Seidman Christine E 4

What Happened

• Christine E. Seidman, a director of Merck & Co. (MRK), was granted a derivative award on 2026-03-31 consisting of 67.545 phantom stock units valued at $120.29 each, for a total grant value of $8,125.
• The transaction is coded as an award/acquisition (A) rather than a market purchase or sale; these are phantom units (derivative), not issuance of actual shares.

Key Details

• Transaction date: 2026-03-31; grant price/value used: $120.29 per unit; total value: $8,125.
• Security: Phantom stock units (derivative award) to be settled 100% in cash upon the reporting person's termination of service per the company's deferred directors' compensation plan (footnote F2).
• Footnotes: F1 indicates 1-for-1 conversion basis; F3 notes holdings may include shares from dividend reinvestment transactions.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Timeliness: Report filed 2026-04-01 for a period ending 2026-03-31 — filing appears timely (no late filing flag).

Context

• This grant is routine director compensation (phantom stock units) and is not a market purchase or sale; it does not necessarily signal a personal buy or sell decision by the insider.
• Because the units are cash-settled upon termination, Seidman did not receive tradable common shares from this grant.